BET Inhibitor CPI-0610 Shows Potential as Treatment in MF
Lucia Masarova, MD, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the efficacy of CPI-0610 in the phase 2 MANIFEST (NCT02158858) trial in patients with myelofibrosis. Masarova says that CPI-0610, a bromodomain, and extra-terminal (BET) inhibitor holds promise in patients […]